USA News Group News
Commentary
Issued on behalf of Avant Technologies
Inc.
VANCOUVER, BC, Jan. 29,
2025 /PRNewswire/ -- USA News Group News Commentary – As
the new administration starts to make its mark in the United States, President Trump recently
announced a $500 billion AI
infrastructure investment in the country, which could have major
ramifications on the standard of living of Americans and the world.
Healthcare industry leaders are rapidly adopting artificial
intelligence (AI) tech into their operations, as analysts at
Technavio project a $125.7
billion growth in the Smart Healthcare Market by 2028. The
World Economic Forum (WEF) recently touted 5 ways that AI is
transforming healthcare, that included brain scan interpretations,
bone fracture identification, assessing ambulance needs, clinical
chatbots to guide healthcare decisions, and detecting early signs
of more than 1,000 diseases. In terms of investment potential, the
market is still at the beginning of the rush, with recent
developments coming from innovators such as Avant Technologies,
Inc. (OTCQB: AVAI), Moderna, Inc. (NASDAQ: MRNA),
Merck & Co., Inc. (NYSE: MRK), GE HealthCare
Technologies Inc. (NASDAQ: GEHC), and Teladoc Health,
Inc. (NYSE: TDOC).
The article continued: Recently Spotify's founder
Daniel Ek's new HealthTech startup
Neko Health secured a $260
million financing, valuing the company at approximately
$1.8 billion. As part of the
announcement by Trump of "Project Stargate", Oracle Chairman
Larry Ellison touted AI's potential
for early cancer detection and treatment development.
Avant Technologies to Play Key Role in Ainnova's U.S. FDA
Clinical Study for Its Vision AI Platform
Avant Technologies, Inc. (OTCQB: AVAI), an emerging
leader in AI-driven healthcare innovation, and its partner,
Ainnova Tech, a leading healthcare technology company
focused on revolutionizing early disease detection using AI, today
announced that Avant has started the budgeting process to
fund Ainnova's upcoming interactions with the U.S. Food
and Drug Administration (FDA). Ainnova will begin by
requesting a pre-submission meeting with the FDA for
guidance on the clinical testing needed for its Vision AI platform
in the early detection of diabetic retinopathy, which will
culminate with an FDA 510(k) submission to obtain clearance from
the FDA to market its technology.
Ai-nova Acquisition Corp. (AAC), the company formed by
the partnership between Avant and Ainnova to advance and
commercialize Ainnova's technology portfolio, including its
"Vision AI" platform and its versatile retinal cameras, has the
licensing rights for this portfolio in the U.S., so the success of
Ainnova's interactions with the FDA are paramount to
marketing the technology portfolio in the
United States.
For medical device applicants like Ainnova, the
FDA's pre-submission program is useful to determine a clear
regulatory pathway for the successful launch of the device,
including the number of patients and the number of clinics needed
to generate the necessary clinical data for the FDA to make
an informed decision on Ainnova's Vision AI platform. For
Avant, the pre- submission meeting will help define a
precise budget for the strategic partnership's entire FDA
process.
Ainnova expects to submit its Pre-Sub application in the coming
weeks and expects to meet with the FDA for its Pre-Sub
meeting in late March/early April
2025. Additionally, Ainnova will also interact with the
FDA to devise a plan to obtain clearance for four algorithms
it recently acquired the exclusive licensing rights to, which
include early detection for cardiovascular risk, prediabetes and
Type 2 diabetes, fatty liver disease, and chronic kidney
disease.
Late last year, Avant announced a game-changing
collaboration with pharma giant Roche, highlighting
Avant's ability to partner with global healthcare leaders
and leverage its innovative technologies for real-world impact.
Together with Ainnova and Salud 360, Avant set
forth to launch a pilot program to combat diabetic retinopathy has
been launched in Costa Rica. This
initiative uses VisionAI to automate retinal image analysis,
identifying early disease markers and facilitating timely
interventions. If successful, the program aims for broader adoption
in the United States, Canada, and Europe through AAC.
"At Roche, we are committed to timely diagnosis of
diseases to improve clinical outcomes and thus contribute to the
sustainability of the healthcare system," said, Alvaro Soto, General Manager of Roche
Central America, Caribbean, and Venezuela. "By leveraging technology, we
seek to improve lives, optimize diagnoses, and ensure that every
patient has access to timely and effective treatment. With this
model, we not only seek to address the problem of diabetic
retinopathy, but also to establish a replicable path for other
diseases that require innovative solutions."
CONTINUED… Read this and more news for Avant Technologies
Inc.
https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
Other recent industry developments and happenings in the
market include:
Moderna, Inc. (NASDAQ: MRNA), saw its shares surge 14%
upon the announcement of Project Stargate, especially due to
Larry Ellison's elaboration on how
AI could play a crucial role in gene-sequencing cancerous tumors to
formulate personalized mRNA vaccines, and produce them robotically
within 48 hours. Although not directly related to the announcement,
the market's reaction indicated optimism over Moderna's
potential role in the AI-driven healthcare future.
As talked about at the recent J.P. Morgan Healthcare
Conference, Moderna reiterated that it continues to
demonstrate the potential clinical benefit of its individualized
neoantigen therapy (INT) (mRNA-4157). Moderna and partners
Merck & Co., Inc. (NYSE: MRK) rapidly expanded clinical
studies to additional tumor types, and that the Phase 3 clinical
trial for adjuvant melanoma successfully completed enrollment in
2024.
Merck has been quite active in AI adoption, having
integrated Quris-AI's Bio-AI platform, and recently
collaborating with Purdue
University and Eli Lilly to speed evolution of
pharma manufacturing. Earlier in December
2023, Merck launched the first ever AI solution to
integrate drug discovery and synthesis, through
its AIDDISON™ drug discovery software, a
software-as-a-service platform that bridges the gap between virtual
molecule design and real-world manufacturability
through SynthiaTM retrosynthesis software application
programing interface (API) integration.
GE HealthCare Technologies Inc. (NASDAQ: GEHC), recently
signed a $247 million deal to bolster
diagnostic services in the UK, which will see the delivery of over
100 device to Nuffield Health's hospitals. The partnership
aims to address key healthcare challenges and promote sustainable
healthcare practices, by leveraging AI-enabled systems.
"We look forward to supporting Nuffield Health with
advanced imaging technologies and solutions to assist their
clinical teams in providing exceptional care and enhancing outcomes
to meet the growing patient demand," said Simon McGuire, President of GE
HealthCare Northern & Eastern Europe Zone. "This long-term
collaboration is a major milestone for GE HealthCare in the
UK's independent sector, built on a customised approach to address
the needs and goals of Nuffield Health and one that is
aligned to GE HealthCare's strategy of working closely with
our customers as a strategic adviser and partner to help solve
health system challenges."
Teladoc Health, Inc. (NYSE: TDOC) recently announced a
new collaboration with Amazon to expand Teladoc's
industry-leading chronic condition programs. Customers of Amazon
that are eligible for Teladoc Health's diabetes, hypertension,
pre-diabetes and weight management programs can now seamlessly
discover and enroll in these benefits directly through
Amazon's Health Benefits Connector, previously known as
Health Condition Programs.
"This partnership helps deliver on our strategy to bring greater
value to our customers in our individual solutions and across our
integrated offerings," said Chuck
Divita, CEO of Teladoc Health. "By enabling customers
to discover and enroll in our programs on Amazon, this
effort will improve access to needed care and help people manage
their health in an easier and more convenient way."
Teladoc Health has more than 1 million active
enrollees across its chronic condition programs, which leverage
connected devices, data-driven personalization and expert coaching
to support sustainable behavior change and improved cardiometabolic
health.
Source:
https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
CONTACT:
USA NEWS
GROUP
info@usanewsgroup.com
(604)
265-2873
DISCLAIMER: Nothing in this publication should be
considered as personalized financial advice. We are not licensed
under securities laws to address your particular financial
situation. No communication by our employees to you should be
deemed as personalized financial advice. Please consult a licensed
financial advisor before making any investment decision. This is a
paid advertisement and is neither an offer nor recommendation to
buy or sell any security. We hold no investment licenses and are
thus neither licensed nor qualified to provide investment advice.
The content in this report or email is not provided to any
individual with a view toward their individual circumstances.
USA News Group is a wholly-owned
subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been
paid a fee for Avant Technologies Inc. advertising and digital
media from the company directly. There may be 3rd parties who may
have shares Avant Technologies Inc., and may liquidate their shares
which could have a negative effect on the price of the stock. This
compensation constitutes a conflict of interest as to our ability
to remain objective in our communication regarding the profiled
company. Because of this conflict, individuals are strongly
encouraged to not use this publication as the basis for any
investment decision. The owner/operator of MIQ own shares of Avant
Technologies Inc. which were purchased in the open market. MIQ
reserves the right to buy and sell, and will buy and sell shares of
Avant Technologies Inc. at any time thereafter without any further
notice. We also expect further compensation as an ongoing digital
media effort to increase visibility for the company, no further
notice will be given, but let this disclaimer serve as notice that
all material disseminated by MIQ has been approved by the above
mentioned company; this is a paid advertisement, and we own shares
of the mentioned company that we will sell, and we also reserve the
right to buy shares of the company in the open market, or through
other investment vehicles. While all information is believed to be
reliable, it is not guaranteed by us to be accurate. Individuals
should assume that all information contained in our newsletter is
not trustworthy unless verified by their own independent research.
Also, because events and circumstances frequently do not occur as
expected, there will likely be differences between any predictions
and actual results. Always consult a licensed investment
professional before making any investment decision. Be extremely
careful, investing in securities carries a high degree of risk; you
may likely lose some or all of the investment.
Logo -
https://mma.prnewswire.com/media/2603685/5140731/USA_News_Group_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/potential-revolution-in-healthcare-brewing-powered-by-ai-innovation-302363261.html
SOURCE USA News Group
